Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it bought back 180,000 H-shares on 10 June 2026 via on-market transactions at prices between HK$3.33 and HK$3.35 per share, representing a volume-weighted average cost of HK$3.34. The total consideration was HK$0.60 million.

Prior to the transaction, Weigao Group had 4.46 billion issued shares (excluding 57.69 million treasury shares). Following the repurchase, the number of issued shares outstanding declined by 180,000 to 4.46 billion, while treasury shares increased to 57.87 million. The repurchased shares, equal to 0.004% of the company’s issued share capital, are being held in treasury and have not been cancelled, leaving total issued shares unchanged at 4.52 billion.

The buyback forms part of a mandate approved on 29 May 2026 that authorises repurchases of up to 446.46 million shares. Cumulative purchases under this mandate now stand at 540,000 shares, or 0.12% of the shares outstanding on the mandate date. In line with Hong Kong Stock Exchange rules, Weigao Group is restricted from issuing new shares or disposing of treasury shares until 10 July 2026.

The company confirmed that all repurchase activities complied with Main Board and other regulatory requirements.